INTRODUCTION
============

The most feared complication of transrectal prostate biopsy is urosepsis which may be increasing in frequency from \<1% 2 decades ago to approximately 2%--3% in recent studies \[[@B1][@B2][@B3]\]. The predominant causative organism is *Escherichia coli* \[[@B2]\]. The mechanism for this complication is that the transrectal biopsy approach involves penetrating the rectal mucosa and subsequently risks inoculating prostatic tissue, which is quite vascular, with bowel flora.

Prostate biopsy is a common procedure with over 1 million biopsies performed per year in the United States \[[@B4]\]. Therefore, even a low rate of complications can cause harm to significant numbers of patients. The estimated economic impact of urosepsis post transrectal biopsy in England and Wales may be up to £11,000,000 annually \[[@B5]\].

The benefit of prophylactic antibiotics in reducing infection after prostate biopsy was definitively established by a Cochrane review \[[@B6]\]. However, the authors did not consider current concerns regarding fluoroquinolone resistance.

Up to one quarter of men undergoing prostate biopsy in recent series are colonized with rectal flora demonstrating fluoroquinolone resistance \[[@B7][@B8]\]. It appears that the number of biopsies is not associated with the development of resistance and that once resistance develops it tends to persist \[[@B7]\]. Fluoroquinolone resistance is a significant clinical concern as, in *E. coli* bacteraemia, fluoroquinolone resistance has been independently associated with mortality due to difficulties in initiating effective antibiotic therapy \[[@B9]\].

Well known risk factors for post transrectal biopsy urosepsis include recent hospitalization, recent antibiotic use---particularly fluoroquinolones, diabetes and recent overseas travel \[[@B1][@B2][@B10][@B11][@B12]\]

In the context of emerging fluoroquinolone resistance this paper will describe a number of possible interventions aimed at reducing infective complications after prostate biopsy.

METHODOLOGY
===========

A systematic review of the literature was undertaken to assess publications on prevention of sepsis af ter transrectal ultrasound (TRUS) biopsy, [Fig. 1](#F1){ref-type="fig"}. The review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria \[[@B13]\]. The Search was conducted using literature databases PubMed and Ovid MEDLINE using the terms \"antibiotic,\" \"prostatic neoplasms,\" \"infection,\" \"prophylaxis,\" \"resistance\" (and their MeSH terms, synonyms) related to \"cancer\" in August 2015. Other search terms used to identify particular techniques included \"rectal preparation,\" \"bowel preparation,\" \"enema\", \"suppository,\" \"rectal swab,\" \"culture directed,\" \"disposable,\" and \"transperineal.\" The search was limited to English language articles considering humans published between January 2000 and August 2015. \"Cascading\" was used to identify references cited in these articles helped identify relevant and significant publications not previously included in the search. The results of key papers are summarised in [Table 1](#T1){ref-type="table"}.

DISCUSSION
==========

Antibiotic resistance and antibiotic prophylaxis
------------------------------------------------

A large study of 75,000 Canadian men reported rising rates of post biopsy infection requiring readmission in from 0.6% in 1996 to 3.6% in 2005 which was thought to be due to rising antibiotic resistance rates, particularly fluoroquinolone resistant *E. coli* \[[@B3]\]. The findings were supported by Carignan et al. \[[@B2]\] who described, from 2002 to 2011, increases in infective complications from 0.52% to 2.15% in conjunction with increases in the ciprofloxacin minimum inhibitory concentration (MIC) amongst those with infective complications. This suggests increasing ciprofloxacin resistance may be a contributing mechanism to the overall increase of infective complications.

Further, Carignan et al. \[[@B2]\] noted that the mean MIC of fluoroquinolone sensitive isolates increased across their study; such that, following a single dose, prostatic concentrations of ciprofloxacin may in many cases actually be below the MIC 24--48 hours after biopsy during which time the epithelial break has not been healed which implies a significant risk of infection \[[@B2]\]. However, we did not identify any recent studies demonstrating an advantage to multiple compared to single dosing regimens. A related point is that antibiotic prophylaxis administered too early before a procedure may be ineffective and that multiple doses of potentially unnecessary antibiotics increases concerns regarding the development of antibiotic resistance.

Another recent contributor to antibiotic resistance is the rising prevalence of the extended spectrum beta lactamase phenotype amongst *Enterobacteriaciae* such as *E. coli* and *Klebsiella* species which confers increased resistance to fluoroquinolones \[[@B14]\].

Augmented prophylactic antibiotics
----------------------------------

The Australian therapeutic guidelines currently recommend ciprofloxacin 500 mg per oral (PO) 60--120 minutes before a transrectal prostate biopsy \[[@B12]\]. A large multicentre study of 9,015 biopsies demonstrated an overall reduction of infective complications from 1.19% to 0.57% after the introduction of augmented prophylaxis with either gentamicin 120 mg or cefazolin 1- to 2-g intramuscular administered in addition to ciprofloxacin 500 mg PO 1 hour before and again the evening after the biopsy \[[@B15]\]. Batura et al. \[[@B16]\] demonstrated the addition of amikacin 1 g intravenous (IV) immediately before the procedure to their existing prophylactic antibiotic regime, which included 500 mg twice daily (BD) PO ciprofloxacin 2 days before through 5 days after and 500 mg per rectum metronidazole once after the procedure, significantly lowered infective complications decreased from 3.9% to 1.4% and the relative risk of bacteraemia decreased by 90% \[[@B16]\].

Rectal swabs and culture directed antibiotic prophylaxis
--------------------------------------------------------

Rather than relying on empirical antibiotic prophylaxis, some advocate cultures f rom rectal swabs to direct specific antibiotic therapy if resistant organisms, such as fluoroquinolone resistant bacteria, are identified. A recent study of 487 patients reported that culture directed antibiotics based on the results of a rectal swab reduced infective complications from 2.9% to 1.9% compared to empirical prophylactic antibiotic therapy \[[@B8]\]. A recent North American study reported a significant reduction in hospitalization of 1.19% to 0.47% after the addition of culture directed antibiotic prophylaxis compared to their historical practice of empirical antibiotic prophylaxis \[[@B15]\]. Taylor et al. \[[@B17]\] used a ciprofloxacin based culture method to assess for fluoroquinolone resistance in rectal swabs. They found ciprofloxacin resistance in 20% of patients. In their study of 457 men they found that targeted antimicrobial prophylaxis reduced infective complications such that 38 rectal swabs would preclude 1 infective complication. However, their results were not statistically significant. They calculated a saving in favour of targeted biopsy of \$4,449 for each infective complication averted \[[@B17]\]. The authors of each of these studies suggested that rectal swab culture directed antibiotic prophylaxis may be a cost effective manner to manage the issue of increasing fluoroquinolone resistance. Qi et al. \[[@B18]\] investigated the mechanisms for antibiotic resistance in rectal swabs and found it results from a heterogeneous group of phenotypes which supports the use of culture directed antibiotic prophylaxis rather than extended generic antibiotic prophylaxis. The main limitation of rectal swab cultures is that they must be taken 24--48 hours prior to the biopsy which complicates practicalities \[[@B17]\].

Disinfectant rectal cleansing, enemas and suppositories
-------------------------------------------------------

The 2011 Cochrane review evaluated the utility of a disinfectant enema. No differences were found in a direct comparison of prophylactic antibiotics and disinfectant enemas. Two studies considered the addition of a disinfectant enema to antibiotics and found it may reduce the incidence of bacteraemia compared to antibiotics alone \[[@B6]\].

Park et al. \[[@B19]\] describe the variety of rectal disinfectants: bisacodyl, phosphate and povidone-iodine administered as enemas or suppositories. The different techniques translated to a range of septic complications 0.2%--9.3% and overall infective complications 2.6%--23.6% \[[@B19]\].

Park et al. \[[@B19]\] recently demonstrated that a povidoneiodine suppository or enema reduced bacterial colony counts from rectal swabs by approximately a factor of one thousand from around 10^6^ to 10^3^. Park et al. \[[@B19]\] describe a series of 1,684 patients treated with a combination of prophylactic antibiotics and povidone-iodine suppository. In this series they reported zero septic complications and a low (0.65%) overall infective complications. Unfortunately their antibiotic regime was not similar to other studies (a 3rd generation cephalosporin and cefixime 100 mg PO for 5 days) and so their results may not be directly comparable to other studies. Recently, Abughosh et al. \[[@B11]\] performed a randomized prospective trial of 865 men demonstrated a nonstatistically significant reduction in septic complications of 1.6% to 1.0% with the addition of povidone-iodine rectal cleansing to oral ciprofloxacin \[[@B11]\]. The authors suggested that povidone-iodine rectal disinfectant may be a useful adjunct to antibiotic prophylaxis, particularly for patients at risk of fluoroquinolone resistance, as they felt it was quick, inexpensive and easy to perform.

Disinfecting biopsy needles
---------------------------

Another approach described by Issa et al. \[[@B20]\] in 2013 involved disinfecting biopsy needles between each core using formaldehyde. They reported a reduction in infective complications by two-thirds compared to historical data from their institution. An additional benefit of this technique is that it is not subject to concerns regarding fluoroquinolone resistance and the authors demonstrated *ex vivo* that such isolates were still susceptible to formaldehyde. The authors estimated that the technique involved 3.9 mg of formaldehyde which is lower than the maximum daily exposure recommended by the environmental protection agency of 14 mg. However, a 2010 study found no significant added benefit from a povidone-iodine solution to disinfect biopsy needles between cores when standard antibiotic prophylaxis was employed \[[@B21]\]. Other methodologies include dipping the needle into betadine between biopsies or wiping the biopsy specimen off the needle with alcohol. Although supportive data on these last 2 methods is lacking, washing the needle in formaldehyde produces better cores for analysis than swiping onto material such as paper \[[@B22]\].

Disposable biopsy needles
-------------------------

Tuncel et al. \[[@B23]\] reported that the use of a disposable needle guide, compared to a reusable needle guide disinfected between patients, significantly reduced the number of fevers and urinary tract infections after biopsy \[[@B23]\]. These results were not supported by a later study by Gurbuz et al. \[[@B24]\] who observed no difference. Both studies had similar antibiotic prophylaxis and disinfection regimes and it may be that the differences were due to technical differences in the model of needle guide used.

Number and size of needles
--------------------------

A recent study has demonstrated that the number of biopsy needles is proportional to the infection risk. The study suggested an increasing risk of infective complications with 6, 12, and 18 needles. However, the study did not investigate the number of severe infections such as sepsis or measure infection severity as indicated by hospitalizations \[[@B25]\]. Another small study suggested that the size of the biopsy needle was not associated with either cancer detection rate or the number of infective complications \[[@B26]\]. These studies suggest it may be prudent for a urologist, in the context of a palpable nodule or targeted biopsy, to take fewer cores if a patient is at elevated risk of infection.

Transperineal biopsy
--------------------

Transperineal biopsy is a novel prostate biopsy technique. The transperineal approach enables the urologist to thoroughly swab the perineum with a disinfectant solution to eliminate skin flora \[[@B27]\]. Additionally, unlike a transrectal approach, transperineal biopsy avoids penetrating bowel mucosa and therefore minimizes blood exposure to bowel flora. Transperineal biopsy, in combination with variable antibiotic prophylaxis, has been shown to have a near-zero septic complication rate with a recent Australian study of 6,609 biopsies resulting in only 5 hospital re-admissions for sepsis \[[@B28]\]. Another study of 634 patients, also treated with amikacin 500 mg IV at induction and ciprofloxacin 500 mg BD for 3 days, had zero episodes of sepsis \[[@B29]\]. Some authors suggest that transperineal biopsy may not necessitate antibiotic prophylaxis and the avoidance of unnecessary antibiotic therapy can be considered good antibiotic stewardship \[[@B28]\]. Australian guidelines state that antibiotic prophylaxis may or may not be required, but suggest 2 g IV cephazolin 15--30 minutes beforehand if antibiotic prophylaxis is desired \[[@B12]\].

Magnetic resonance imaging
--------------------------

Recent advances in multiparametric magnetic resonance imaging (MRI) allow an expanding clinical scope for noninvasive imaging. Some authors argue MRI may be more useful than a TRUS biopsy in specific situations, such as anterior tumours, which reduces the need for repeated TRUS biopsies therefore incidentally lowering biopsy complication rates \[[@B4][@B30]\].

CONCLUSIONS
===========

Antibiotic resistance, particularly fluoroquinolone resistance, appears to be driving an increase in the number of infective complications, including urosepsis, occurring after prostate biopsy. Effective strategies to reduce this feared complication include augmented prophylaxis, rectal swab culture directed antibiotic prophylaxis and a transperineal biopsy approach. Needle disinfection, minimizing the number of biopsy needles and rectal disinfectants may also be of use.
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###### Measures taken in selected studies to reduce infective complications from prostate biopsy

![](icu-57-94-i001)

  Source                        No.     Year   Intervention                                                                                                                                                 Comparator                                                                             Measure                              Outcome                           Level of evidence
  ----------------------------- ------- ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------- ------------------------------------ --------------------------------- -------------------
  Batura et al. \[[@B16]\]      871     2014   Augmented prophylaxis, 1-g amikacin IV immediately beforehand                                                                                                500-mg ciprofloxacin for 7 days and 500-mg PR metronidazole afterward                  All infective complications          Reduced from 3.9% to 1.4%         4
  Womble et al. \[[@B15]\]      8,505   2015   Augmented prophylaxis with either gentamicin 120 mg IM or 1- to 2-g cefazolin                                                                                Ciprofloxacin 500 mg PO 1 hour before biopsy and again after biopsy                    Infection related ospitalizations    Reduced from .19% to 0.57%        4
  Womble et al. \[[@B15]\]      3,911   2015   Rectal swab culture directed antibiotic prophylaxis                                                                                                          Ciprofloxacin 500 mg PO 1 hour before biopsy and again after biopsy                    Infection related hospitalizations   Reduced from 1.19% to 0.47%       4
  Taylor et al. \[[@B17]\]      457     2012   Rectal swab culture directed antibiotic prophylaxis                                                                                                          Ciprofloxacin PO 500 mg 2 hours prior and 12 hours after biopsy                        All infective complications          Reduced from 2.6% to Nil^\*^      4
  Dai et al. \[[@B8]\]          487     2015   Rectal swab culture directed antibiotic prophylaxis                                                                                                          3 Doses 500-mg ciprofloxacin before biopsy                                             All infective complications          Reduced from 2.9% to 1.9%^\*^     4
  Abughosh et al. \[[@B11]\]    865     2013   povidone-iodine rectal cleansing                                                                                                                             Ciprofloxacin 1,000 mg for 3 days prior                                                Septic complications                 Reduced from 1.6% to 1.0%^\*^     4
  Park et al. \[[@B19]\]        1,684   2014   povidone-iodine suppository, single IV 3rd generation cephalosporin immediately before biopsy and cefixime 100 mg PO for 5 days starting the day of biopsy   Nil                                                                                    All infective complications          0.65%                             4
  Issa et al. \[[@B20]\]        2,632   2013   Formaldehyde needle disinfection                                                                                                                             500-mg ciprofloxacin started on day of procedure                                       Urinary tract infection or sepsis    Reduced from 0.8% to 0.3%^\*^     4
  Koc et al. \[[@B21]\]         180     2010   povidone-iodine solution to disinfect biopsy needles                                                                                                         500 mg BD ciprofloxacin started on day of procedure                                    All infective complications          Reduced from 7.2% to 4.8%^\*^     2b
  Grummet et al. \[[@B28]\]     6,609   2014   Transperineal approach with variable                                                                                                                         Nil                                                                                    Sepsis                               0.08%                             4
  Vyas et al. \[[@B29]\]        634     2014   Transperineal approach with amikacin 500 mg IV at induction and ciprofloxacin 500 mg BD for three days                                                       Nil                                                                                    Sepsis                               Zero                              4
  Ghafoori et al. \[[@B25]\]    180     2015   Twelve core biopsy technique                                                                                                                                 Eighteen core biopsy technique, with antibiotic prophylaxis                            All infectious complications         Reduced from 58.3% to 38.3%       2b
  McCormack et al. \[[@B26]\]   105     2012   16-G biopsy needle                                                                                                                                           18-G biopsy needle with antibiotic prophylaxis                                         All infective complications          Increased from 3.8% to 4.0%^\*^   4
  Tuncel et al. \[[@B23]\]      198     2008   Disposable needle guide                                                                                                                                      Reusable needle guide disinfected with 3.2% glutaraldehyde solution between patients   Acute urinary infection              Reduced from 8.2% to 2.3%         2b
  Gurbuz et al. \[[@B24]\]      55      2011   Disposable needle guide                                                                                                                                      Reusable needle guide disinfected with 3.2% glutaraldehyde solution between patients   Symptomatic urinary infection        Increased from 3.9% to 4.0%^\*^   2b

IV, intravenous; PR, per rectum; IM, intramuscular; PO, per oral; Nil, not described or not available; bd, twice daily.

^\*^Result not statistically significant p\<0.05.
